Positive Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder

&nbsp

Recommendation from the independent Data Monitoring Committee (DMC) to continue the PORTICO trial based on positive safety data from the initial 167 randomized patients.

PORTICO plans to recruit 188 patients.

&nbsp

MADRID, Spain and BOSTON, July 05, 2023 (GLOBE NEWSWIRE) -- ORYZON Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today reports new preliminary blinded aggregate safety data from its ongoing Phase IIb PORTICO trial, investigating vafidemstat in Borderline Personality Disorder (BPD).

'Pharmacology > BS' 카테고리의 다른 글

Daxor Corporation Awarded $1.1 Million Contract from the United States Defense Health Agency for Added Capabilities to its Point-of-Care Blood Volume Analyzer (0)	2023.07.06
Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease (0)	2023.07.06
InnoCare Announces First Psoriasis Patient Dosed in Clinical Trial of TYK2 Allosteric Inhibitor ICP-488 in China (0)	2023.07.05
Lunit's AI-Powered Lung Cancer Screening Solution Significantly Affects Radiologists' Diagnostic Determination (0)	2023.07.04
CANbridge to Continue CAN008 Phase 2 Trial in Glioblastoma Multiforme (GBM) in China Based on Interim Analysis of Independent Data Monitoring Committee (0)	2023.07.04

'Pharmacology > BS' 카테고리의 다른 글

티스토리툴바